IL86086A - Fusion protein with activities of interleukin-2 and gm-csf and pharmaceutical compositions containing said protein - Google Patents
Fusion protein with activities of interleukin-2 and gm-csf and pharmaceutical compositions containing said proteinInfo
- Publication number
- IL86086A IL86086A IL8608688A IL8608688A IL86086A IL 86086 A IL86086 A IL 86086A IL 8608688 A IL8608688 A IL 8608688A IL 8608688 A IL8608688 A IL 8608688A IL 86086 A IL86086 A IL 86086A
- Authority
- IL
- Israel
- Prior art keywords
- protein
- thr
- asp
- csf
- constituent
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 50
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 47
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title claims 4
- 108010002350 Interleukin-2 Proteins 0.000 title abstract description 28
- 102000000588 Interleukin-2 Human genes 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title description 7
- 102000037865 fusion proteins Human genes 0.000 title description 6
- 230000000694 effects Effects 0.000 title description 5
- 230000001588 bifunctional effect Effects 0.000 claims abstract description 18
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 6
- 201000011510 cancer Diseases 0.000 claims abstract description 5
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 239000000470 constituent Substances 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000004071 biological effect Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 238000010353 genetic engineering Methods 0.000 abstract description 3
- 230000002281 colonystimulating effect Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 32
- 102100020873 Interleukin-2 Human genes 0.000 description 26
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 23
- 239000013612 plasmid Substances 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 108010093581 aspartyl-proline Proteins 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 2
- RRRRCRYTLZVCEN-HJGDQZAQSA-N Thr-Leu-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O RRRRCRYTLZVCEN-HJGDQZAQSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WXERCAHAIKMTKX-ZLUOBGJFSA-N Ala-Asp-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O WXERCAHAIKMTKX-ZLUOBGJFSA-N 0.000 description 1
- VPSHHQXIWLGVDD-ZLUOBGJFSA-N Asp-Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VPSHHQXIWLGVDD-ZLUOBGJFSA-N 0.000 description 1
- LKIYSIYBKYLKPU-BIIVOSGPSA-N Asp-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)N)C(=O)O LKIYSIYBKYLKPU-BIIVOSGPSA-N 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 108010054278 Lac Repressors Proteins 0.000 description 1
- WIDZHJTYKYBLSR-DCAQKATOSA-N Leu-Glu-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WIDZHJTYKYBLSR-DCAQKATOSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 1
- GRIUMVXCJDKVPI-IZPVPAKOSA-N Thr-Thr-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GRIUMVXCJDKVPI-IZPVPAKOSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873712985 DE3712985A1 (de) | 1987-04-16 | 1987-04-16 | Bifunktionelle proteine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL86086A0 IL86086A0 (en) | 1988-09-30 |
| IL86086A true IL86086A (en) | 1995-01-24 |
Family
ID=6325799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL8608688A IL86086A (en) | 1987-04-16 | 1988-04-15 | Fusion protein with activities of interleukin-2 and gm-csf and pharmaceutical compositions containing said protein |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0288809B1 (enExample) |
| JP (1) | JP2667193B2 (enExample) |
| KR (1) | KR970000187B1 (enExample) |
| AR (1) | AR242991A1 (enExample) |
| AT (1) | ATE79135T1 (enExample) |
| AU (1) | AU613022B2 (enExample) |
| CA (1) | CA1322157C (enExample) |
| DE (2) | DE3712985A1 (enExample) |
| DK (1) | DK170741B1 (enExample) |
| ES (1) | ES2033981T3 (enExample) |
| FI (1) | FI98830C (enExample) |
| GR (1) | GR3006141T3 (enExample) |
| HU (1) | HU204303B (enExample) |
| IE (1) | IE61574B1 (enExample) |
| IL (1) | IL86086A (enExample) |
| NO (1) | NO176922C (enExample) |
| NZ (1) | NZ224247A (enExample) |
| PH (1) | PH25327A (enExample) |
| PT (1) | PT87237B (enExample) |
| ZA (1) | ZA882659B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5662896A (en) * | 1988-03-21 | 1997-09-02 | Chiron Viagene, Inc. | Compositions and methods for cancer immunotherapy |
| US6406697B1 (en) | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| WO1990012877A1 (en) * | 1989-04-19 | 1990-11-01 | Cetus Corporation | Multifunctional m-csf proteins and genes encoding therefor |
| US5108910A (en) * | 1989-08-22 | 1992-04-28 | Immunex Corporation | DNA sequences encoding fusion proteins comprising GM-CSF and IL-3 |
| DK0489116T3 (da) * | 1989-08-22 | 1994-05-02 | Immunex Corp | Fusionsproteiner omfattende GM-CSF og IL-3 |
| US5073627A (en) * | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| US5376367A (en) * | 1991-11-22 | 1994-12-27 | Immunex Corporation | Fusion proteins comprising MGF and IL-3 |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| ES2221717T3 (es) | 1997-12-08 | 2005-01-01 | Emd Lexigen Research Center Corp. | Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general. |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| US6617135B1 (en) | 1999-08-09 | 2003-09-09 | Emd Lexigen Research Center Corp. | Multiple cytokine protein complexes |
| CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
| JP4553290B2 (ja) * | 1999-11-30 | 2010-09-29 | 塩野義製薬株式会社 | ケモカインｓｌｃ−ｉｌ２融合タンパク質とその遺伝子 |
| DK1252192T3 (da) | 2000-02-11 | 2006-11-20 | Merck Patent Gmbh | Forbedring af antistofbaserede fusionsproteiners serumhalveringstid |
| RU2272644C2 (ru) | 2000-06-29 | 2006-03-27 | Мерк Патент Гмбх | Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина |
| KR100900176B1 (ko) | 2001-03-07 | 2009-06-02 | 메르크 파텐트 게엠베하 | 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술 |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| CA2446087C (en) | 2001-05-03 | 2013-06-18 | Stephen D. Gillies | Recombinant tumor specific antibody and use thereof |
| EP2305312B1 (en) | 2001-10-10 | 2015-03-04 | ratiopharm GmbH | Remodelling and glycoconjugation of follicle-stimulating hormone (FSH) |
| BR0214650A (pt) | 2001-12-04 | 2005-05-03 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| JP4494977B2 (ja) | 2002-12-17 | 2010-06-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質 |
| DE602004031341D1 (de) | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| ATE500267T1 (de) * | 2003-07-21 | 2011-03-15 | Transgene Sa | Multifunktionelle cytokine |
| WO2010001414A1 (en) * | 2008-07-03 | 2010-01-07 | Lupin Limited | Expression of heterologous proteins in bacterial system using a gm-csf fusion tag |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985000817A1 (en) * | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
| GB8327880D0 (en) * | 1983-10-18 | 1983-11-16 | Ajinomoto Kk | Saccharomyces cerevisiae |
| EP0158198A1 (en) * | 1984-03-29 | 1985-10-16 | Takeda Chemical Industries, Ltd. | DNA and use thereof |
| WO1985004673A1 (fr) * | 1984-04-10 | 1985-10-24 | Takeda Chemical Industries, Ltd. | Nouvel adn et son utilisation |
| DE3419995A1 (de) * | 1984-05-29 | 1985-12-05 | Hoechst Ag, 6230 Frankfurt | Gentechnologisches verfahren zur herstellung von human-interleukin-2 und mittel zur durchfuehrung dieses verfahrens |
| AU588819B2 (en) * | 1984-10-29 | 1989-09-28 | Immunex Corporation | Cloning of human granulocyte-macrophage colony stimulating factor gene |
| JPS61128889A (ja) * | 1984-11-27 | 1986-06-16 | Green Cross Corp:The | 組換えｄｎａ及び該ｄｎａによる形質転換体 |
| JPH0646957B2 (ja) * | 1985-03-11 | 1994-06-22 | 武田薬品工業株式会社 | インタ−ロイキン−２の製造方法 |
| WO1987002060A1 (en) * | 1985-10-03 | 1987-04-09 | Biogen N.V. | Human granulocyte-macrophage colony stimulating factor-like polypeptides and processes for producing them in high yields in microbial cells |
| DE3541856A1 (de) * | 1985-11-27 | 1987-06-04 | Hoechst Ag | Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens |
| DE3545568A1 (de) * | 1985-12-21 | 1987-07-16 | Hoechst Ag | Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung |
-
1987
- 1987-04-16 DE DE19873712985 patent/DE3712985A1/de not_active Withdrawn
-
1988
- 1988-04-09 DE DE8888105693T patent/DE3873397D1/de not_active Expired - Fee Related
- 1988-04-09 EP EP88105693A patent/EP0288809B1/de not_active Expired - Lifetime
- 1988-04-09 AT AT88105693T patent/ATE79135T1/de not_active IP Right Cessation
- 1988-04-09 ES ES198888105693T patent/ES2033981T3/es not_active Expired - Lifetime
- 1988-04-14 NZ NZ224247A patent/NZ224247A/en unknown
- 1988-04-14 FI FI881743A patent/FI98830C/fi not_active IP Right Cessation
- 1988-04-14 PT PT87237A patent/PT87237B/pt active IP Right Grant
- 1988-04-15 HU HU881966A patent/HU204303B/hu not_active IP Right Cessation
- 1988-04-15 DK DK209188A patent/DK170741B1/da not_active IP Right Cessation
- 1988-04-15 IL IL8608688A patent/IL86086A/en not_active IP Right Cessation
- 1988-04-15 JP JP63093321A patent/JP2667193B2/ja not_active Expired - Fee Related
- 1988-04-15 AU AU14661/88A patent/AU613022B2/en not_active Ceased
- 1988-04-15 CA CA000564322A patent/CA1322157C/en not_active Expired - Fee Related
- 1988-04-15 IE IE114688A patent/IE61574B1/en not_active IP Right Cessation
- 1988-04-15 NO NO881658A patent/NO176922C/no not_active IP Right Cessation
- 1988-04-15 ZA ZA882659A patent/ZA882659B/xx unknown
- 1988-04-15 AR AR88310585A patent/AR242991A1/es active
- 1988-04-16 KR KR1019880004345A patent/KR970000187B1/ko not_active Expired - Fee Related
-
1989
- 1989-04-14 PH PH36799A patent/PH25327A/en unknown
-
1992
- 1992-11-04 GR GR920402185T patent/GR3006141T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5359035A (en) | Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) | |
| IL86086A (en) | Fusion protein with activities of interleukin-2 and gm-csf and pharmaceutical compositions containing said protein | |
| EP0546124B2 (en) | Multidomain hematopoiesis stimulators | |
| US7704709B2 (en) | Modified human granulocyte-colony stimulating factor and process for producing same | |
| JP2541761B2 (ja) | ミュレル管抑制物質様ポリペプチドおよびその製造方法 | |
| US5017692A (en) | Truncated human interleukin-a alpha | |
| KR940005585B1 (ko) | 과립구 대식세포 콜로니 촉진 인자(gm-csf)단백질의 제조방법 | |
| CA1339892C (en) | Preparation of polypeptides having human gamma enterferon activity | |
| CA2191306A1 (en) | Hybrid molecule of formula gm-csf-l-epo or epo-l-gm-csf for hematopoietic stimulation | |
| JP2000060577A (ja) | 成熟ヒトインタ―ロイキン１タンパク質 | |
| JPH0665318B2 (ja) | ヒト成長ホルモンの製造方法 | |
| US5498697A (en) | Protein possessing metastasis-inhibitory activity | |
| AU617999B2 (en) | A genetic engineering process for the preparation of angiogenins | |
| EP0306870A2 (de) | Gamma-Interferon-Derivate, Herstellungsverfahren, Vektoren dafür und Arzneimittel daraus | |
| AU621051B2 (en) | Method for purifying granulocyte-macrophage colony stimulating factor | |
| SU1607690A3 (ru) | Способ стабилизации рекомбинантного фактора некроза опухоли | |
| TW480285B (en) | Enzyme for converting a precursor of a polypeptide into the active form that induces IFN-γ production, the process therefor, and the uses thereof | |
| CA1306208C (en) | Enhanced expression and stabilization of gene products in microorganisms using short selected leader signal sequences | |
| RU2089612C1 (ru) | Рекомбинантная плазмидная днк purvgf, определяющая синтез фактора роста вируса осповакцины штамма л-ивп совместно с бета - галактозидазой escherichia coli, и штамм бактерий escherichia coli, содержащий рекомбинантную плазмидную днк purvgf - продуцент фактора роста вируса осповакцины штамма л-ивп | |
| JPS617296A (ja) | インタ−ロイキン１の遺伝子の精製、クロ−ニング及び特性づけ | |
| Wada et al. | Production of a protein A—lymphotoxin hybrid protein for cancer-targeted therapy | |
| EP0750667B1 (de) | Verwendung von rekombinantem inhibitor aus erythrina caffra zur reinigung von serinproteasen | |
| DE19512937A1 (de) | Neuer Inhibitor des Erythrina caffra Typs und dessen Verwendung zur Reinigung von Serinproteasen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |